Thromb Haemost 2001; 86(02): 715-716
DOI: 10.1055/s-0037-1616120
Letters to the Editor
Schattauer GmbH

Reassessment of the Correlation between the von Willebrand Factor Activity, the PFA-100®, and the Bleeding Time in Patients with von Willebrand Disease

Ioana C. Nitu-Whalley
1   Centre and Haemostasis Unit, Royal Free and University College Medical School, London, UK
,
Christine A. Lee
1   Centre and Haemostasis Unit, Royal Free and University College Medical School, London, UK
,
Cedric Hermans
1   Centre and Haemostasis Unit, Royal Free and University College Medical School, London, UK
› Author Affiliations
Further Information

Publication History

Received 25 November 2000

Accepted after revision 28 March 2001

Publication Date:
12 December 2017 (online)

 

 
  • References

  • 1 Veyradier A, Fressinaud E, Boyer-Neumann C, Trossaert M, Meyer D. von Willebrand factor ristocetin cofactor activity correlates with platelet function in a high shear stress system. Thromb Haemost 2000; 84: 727-8.
  • 2 Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-10.
  • 3 Murdock PJ, Woodhams BJ, Matthews KB, Pasi KJ, Goodall AH. von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost 1997; 78: 1272-7.
  • 4 Fressinaud E, Veyradier A, Truchard F, Martin I, Boyer-Neumann C, Trossaert M, Meyer D. Screening for von Willebrand disease with a new analyser using high shear stress: a study of 60 cases. Blood 1998; 91: 1325-31.
  • 5 Cattaneo M, Federici AB, Lecchi A, Agati B, Lombardi R, Stabile F, Bucciarelli P. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999; 82: 35-9.
  • 6 Nitu-Whalley IC, Riddell A, Lee CA, Pasi KJ, Owens D, Enayat MS, Perkins SJ, Jenkins PV. Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients: a reappraisal using phenotypes, genotypes and molecular modeling. Thromb Haemost 2000; 84: 998-1004.